Elmar Kraus analyst DZ BANK

Currently out of the existing stock ratings of Elmar Kraus, 14 are a HOLD (40%), 21 are a BUY (60%).

Elmar Kraus

Work Performance Price Targets & Ratings Chart

Analyst Elmar Kraus, currently employed at DZ BANK, carries an average stock price target met ratio of 87.5% that have a potential upside of 24.03% achieved within 370 days.

Elmar Kraus’s has documented 69 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GILD, Gilead Sciences at 13-Feb-2025.

Wall Street Analyst Elmar Kraus

Analyst best performing recommendations are on AZN (ASTRAZENECA PLC ADR).
The best stock recommendation documented was for AZN (ASTRAZENECA PLC ADR) at 2/11/2022. The price target of $124.66 was fulfilled within 46 days with a profit of $21.5 (20.84%) receiving and performance score of 4.53.

Average potential price target upside

BIIB Biogen LLY Eli Lilly and Company AZN AstraZeneca PLC ADR GILD Gilead Sciences AMGN Amgen ABBV AbbVie JNJ Johnson & Johnson MRK Merck mpany MDT Medtronic PLC SMMNY Siemens Healthineers AG ADR PFE Pfizer BMY Bristol-Myers Squibb Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sell Since 17-Mar-2026

$175

$-52.6 (-23.11%)

$150

20 days ago
(10-Sep-2026)

0/3 (0%)

$-40.43 (-18.77%)

Buy Since 15-May-2026

$245

$17.4 (7.64%)

$225

27 days ago
(03-Sep-2026)

5/9 (55.56%)

$20.49 (9.13%)

69

Buy Since 04-Mar-2022

$260

$32.4 (14.24%)

$240

1 months 5 days ago
(25-Aug-2026)

57/87 (65.52%)

$39.23 (17.77%)

169

Buy Since 28-Sep-2022

$241

$13.4 (5.89%)

$221

1 months 26 days ago
(04-Aug-2026)

25/42 (59.52%)

$32.55 (15.62%)

152

Hold Since 06-Jan-2023

$215

$-12.6 (-5.54%)

$200

1 months 27 days ago
(03-Aug-2026)

29/38 (76.32%)

$13.18 (6.53%)

220

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Elmar Kraus?

On 2019
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?